ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,974.07
0.00%
Dow Jones
42,906.95
0.00%
US Dollar vs MXN
20.17567
-0.04%
Brent Oil
73.245
0.75%
Bitcoin
96,103.20
1.49%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Canadá
  5. TSXV
  6. Cotinga Pharmaceuticals Inc (COT)

  7. Cotinga Pharmaceuticals Inc (COT) Noticias

COT

Cotinga Pharmaceuticals (COT)

Cotinga Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:TSXV:COT
FechaHoraFuenteTítuloSímboloCompañía
15/10/202007:01PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - COTTSXV:COTCotinga Pharmaceuticals Inc
15/10/202006:55PR Newswire (Canada)IIROC Trading Halt - COTTSXV:COTCotinga Pharmaceuticals Inc
07/11/201915:10PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - COTTSXV:COTCotinga Pharmaceuticals Inc
07/11/201915:09PR Newswire (Canada)IIROC Trading Resumption - COTTSXV:COTCotinga Pharmaceuticals Inc
24/07/201415:20Marketwired CanadaCritical Outcome Technologies Reports Year-End Financial and Operating ResultsTSXV:COTCotinga Pharmaceuticals Inc
23/06/201408:00MarketwiredCritical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALINDTSXV:COTCotinga Pharmaceuticals Inc
17/06/201408:00MarketwiredCritical Outcome Technologies Receives Orphan Drug Designation For COTI-2TSXV:COTCotinga Pharmaceuticals Inc
16/06/201408:00Marketwired CanadaCritical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQFTSXV:COTCotinga Pharmaceuticals Inc
13/06/201418:42Marketwired CanadaCritical Outcome Technologies Inc.: SeeThruEquity Initiates Research CoverageTSXV:COTCotinga Pharmaceuticals Inc
13/06/201408:00MarketwiredCritical Outcome Technologies Invited to Present at 16th International p53 Workshop in SwedenTSXV:COTCotinga Pharmaceuticals Inc
04/06/201408:00MarketwiredCritical Outcome Technologies Inc. Completes FinancingTSXV:COTCotinga Pharmaceuticals Inc
27/05/201415:48Marketwired CanadaCritical Outcome Technologies Inc. Announces Warrant Term AmendmentTSXV:COTCotinga Pharmaceuticals Inc
27/05/201408:00MarketwiredCritical Outcome Technologies Selected to Present at Multiple Investor Conferences in New York CityTSXV:COTCotinga Pharmaceuticals Inc
22/05/201408:00Access WireSeeThruEquity 3rd Annual Microcap Investor Conference To Be Held May 28, 2014TSXV:COTCotinga Pharmaceuticals Inc
01/05/201407:48MarketwiredFinancing Increases Runway to the Clinic for COTI-2, Critical Outcome's Lead Cancer Drug CandidateTSXV:COTCotinga Pharmaceuticals Inc
14/04/201415:30Marketwired CanadaCritical Outcome Technologies Announces Warrant IssuanceTSXV:COTCotinga Pharmaceuticals Inc
04/04/201408:00MarketwiredCritical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian CancerTSXV:COTCotinga Pharmaceuticals Inc
14/03/201408:00MarketwiredCritical Outcome Technologies Reports Third Quarter ResultsTSXV:COTCotinga Pharmaceuticals Inc
26/02/201408:29MarketwiredCritical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2TSXV:COTCotinga Pharmaceuticals Inc
06/02/201408:13MarketwiredCritical Outcome Technologies Completes Private PlacementTSXV:COTCotinga Pharmaceuticals Inc
05/02/201407:00Marketwired CanadaCritical Outcome Technologies Announces Engagement of Maxim Group LLCTSXV:COTCotinga Pharmaceuticals Inc
18/12/201315:48MarketwiredCritical Outcome Technologies Reports Second Quarter ResultsTSXV:COTCotinga Pharmaceuticals Inc
06/12/201315:05MarketwiredCritical Outcome Technologies Awards Stock OptionsTSXV:COTCotinga Pharmaceuticals Inc
06/12/201307:47MarketwiredCritical Outcome Technologies Provides Business and Scientific Update at Annual General MeetingTSXV:COTCotinga Pharmaceuticals Inc
13/11/201307:00Marketwired CanadaCOTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent ProtectionTSXV:COTCotinga Pharmaceuticals Inc
29/10/201315:15Marketwired CanadaCritical Outcome Technologies Announces Warrant Expiry Date AmendmentTSXV:COTCotinga Pharmaceuticals Inc
15/10/201315:30Marketwired CanadaCritical Outcome Technologies Grants Stock OptionsTSXV:COTCotinga Pharmaceuticals Inc
03/10/201308:45Marketwired CanadaCritical Outcome Technologies to Present at the 12th Annual BIO Investor ForumTSXV:COTCotinga Pharmaceuticals Inc
27/09/201315:05Marketwired CanadaCritical Outcome Technologies Reports Fiscal 2014 First Quarter ResultsTSXV:COTCotinga Pharmaceuticals Inc
11/09/201315:05Marketwired CanadaCritical Outcome Technologies Announces Warrant Term AmendmentsTSXV:COTCotinga Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSXV:COT

Su Consulta Reciente

NYSE
NKE
Nike
NYSE
KO
Coca Cola
NASDAQ
GOOGL
Alphabet
NYSE
CVX
Chevron
AMEX
XLE
Energy Select Sector SPDR
COIN
XRPUSD
Ripple
CCOM
SILVER
SILVER
COIN
DOGEUSD
Dogecoin
NASDAQ
QQQ
Invesco QQQ Trust Series 1
SPI
SP500
S&P 500
NYSE
DIS
Walt Disney
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
AMEX
XLV
Health Care Select Sector
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados